Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2007

View Archived Issues

Recent Tibotec, Medivir and Valeant patents report novel anti-hepatitis agents

Medivir reviews 2006

Studies detail stem cell mobilization efficacy of AMD-3100

Association between dopamine agonist use and pathological gambling in RLS

Novel anticancer compounds described in recent patents

Novel therapeutic agents for respiratory disorders described in recent patents

Novel therapeutic agents for transplant rejection disclosed by Astellas

New vaccine therapy may be useful to treat recurrent cancer in the elderly

Noscapine shows efficacy in prostate cancer

Genfit renews alliances

Schering-Plough begins phase I study of Pharmacopeia collaborative compound

Avalon begins drug discovery program targeting MYC oncoprotein

Treatment begins in pivotal program for LX-211 in uveitis

Shire to acquire New River Pharmaceuticals

Disruption of the CXCR4-CXCL12 and VLA4-VCAM-1 axes may sensitize leukemia cells to chemotherapy

Bentley cleared to begin phase II program for Nasulin in India

Athenagen changes name to CoMentis

MIST-B02 shows promise in pilot pharmacokinetic study

Hana anticipates delay in launch of Zensana

AA-4500 successful in treating Dupuytren's contracture

6R-BH4 shows no significant benefit over placebo in poorly controlled hypertension

SD-118 for neuropathic pain completes preclinical testing

Vascular disruption agent BNC-105 begins safety studies in animals

Allon files IND for AL-108 phase II trials in schizophrenia

FDA requests strengthened label warnings for Xolair

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...